Pharma Corporate Strategy – Gilead acquires Calistoga

Today’s announcement that Gilead Sciences is acquiring Calistoga pharmaceuticals for $375M shows that acquisition remains a key strategy for companies looking to add promising new drugs to their pipeline.

Calistoga’s CAL-101 is a PI3-kinase inhibitor that targets cancer and inflammatory diseases. You can read more about the acquisition of Calistoga by Gilead on Biotech Strategy Blog.

, , , , , , , , , , , , , , ,

error: Content is protected !!